Treatment of inflammatory diseases with inhibitors of C5a activity
AssigneeInflaRx GmbH
InventorsRenfeng Guo, Niels C. Riedemann
Life of this patent
Estimating the term…
Abstract
The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
Claims19
A method of treating Hidradenitis suppurativa (HS) or a HS-related disease in a subject, the method comprising:
- administering to the subject in need thereof an effective amount of an agent that inhibits C5a activity in the subject, wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG);
- PASH (PG, acne and Hidradenitis suppurativa);
- and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa).
A method of inhibiting the interaction of a C5a receptor with a C5a receptor ligand to treat Hidradenitis suppurativa (HS) or a HS-related disease in a subject, the method comprising administering to the subject an agent that specifically binds to C5, to the C5a receptor, or to the C5a receptor ligand, thereby inhibiting the interaction of the C5a receptor with the C5a receptor ligand and treating the disease, wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG);
- PASH (PG, acne and Hidradenitis suppurativa);
- and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa).
A method of treating Hidradenitis suppurativa (HS) or an HS-related disease in a subject, the method comprising:
- administering to the subject in need thereof an agent that inhibits C5a activity in the subject in an effective amount to treat HS or the HS-related disease, wherein the agent is selected from the group consisting of Avacopan, IFX-1, INab708, MEDI-7814, ALXN-1007, Eculizumab, ALXN1210, LFG316, ALXN5500, Coversin, RA101495, NOX-D21, Zimura, and ALN-CCS;
- and wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG);
- PASH (PG, acne and Hidradenitis suppurativa);
- and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa).
A method of treating Hidradenitis suppurativa (HS) in a subject, the method comprising:
- administering to the subject in need thereof an agent that inhibits C5a activity in the subject in an effective amount to treat HS, wherein the agent is selected from the group consisting of Avacopan, IFX-1, INab708, MEDI-7814, ALXN-1007, Eculizumab, ALXN1210, LFG316, ALXN5500, Coversin, RA101495, NOX-D21, Zimura, and ALN-CCS.
A method of treating Hidradenitis suppurativa (HS) or a HS-related disease in a subject, the method comprising:
- administering to a subject in need thereof an effective amount of Avacopan to treat HS or the HS-related disease, wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG);
- PASH (PG, acne and Hidradenitis suppurativa);
- and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa).
A method of treating Hidradenitis suppurativa (HS) or a HS-related disease in a subject, the method comprising:
- administering to a subject in need thereof an effective amount of IFX-1 antibody, or an antigen-binding fragment thereof, to treat HS or the HS-related disease, wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG);
- PASH (PG, acne and Hidradenitis suppurativa);
- and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa).
Dependencies are inferred from the claim text.